Literature DB >> 7593619

Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells.

J M Heery1, M Kozak, D M Stafforini, D A Jones, G A Zimmerman, T M McIntyre, S M Prescott.   

Abstract

Oxidative modification of lipoproteins is believed to be important in the genesis of atherosclerosis. We established cultures of smooth muscle cells (SMC) and exposed them to native LDL or oxidized LDL. Oxidized LDL, but not native LDL, was mitogenic as measured by incorporation of [3H]-thymidine into DNA. This effect was concentration dependent, averaged 288% of control, and was blocked by a platelet-activating factor (PAF) receptor antagonist. We hypothesized that phospholipids with PAF-like activity were generated during the oxidation of LDL. To test this hypothesis we extracted phospholipids from copper-oxidized LDL and assayed for PAF-like activity. Phospholipids extracted from oxidized LDL and purified by HPLC induced neutrophil adhesion equivalent to PAF (10 nM) and were mitogenic for smooth muscle cells. These effects were not seen with phospholipids extracted from native LDL and were blocked by two structurally different, competitive antagonists of the PAF receptor. The effects of these lipids were also abolished by pretreating them with PAF acetylhydrolase. Finally, we used Chinese hamster ovary cells that had seen stably transfected with a cDNA for the PAF receptor to confirm that phospholipids from oxidized LDL act via this receptor. We found that PAF (control) and the oxidized phospholipids each induced release of arachidonic acid from the transfected cells, but had no effect on wildtype Chinese hamster ovary cells, which lack the PAF receptor. This effect was also blocked by a PAF receptor antagonist. Thus, phospholipids generated during oxidative modification of LDL may participate in atherosclerosis by stimulating SMC proliferation and leukocyte activation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7593619      PMCID: PMC185883          DOI: 10.1172/JCI118288

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  58 in total

1.  Low density lipoprotein causes general cellular activation with increased phosphatidylinositol turnover and lipoprotein catabolism.

Authors:  L H Block; M Knorr; E Vogt; R Locher; W Vetter; P Groscurth; B Y Qiao; D Pometta; R James; M Regenass
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

2.  Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition.

Authors:  J L Goldstein; Y K Ho; S K Basu; M S Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1979-01       Impact factor: 11.205

3.  Preformed PAF-acether and lyso PAF-acether are bound to blood lipoproteins.

Authors:  J Benveniste; D Nunez; P Duriez; R Korth; J Bidault; J C Fruchart
Journal:  FEBS Lett       Date:  1988-01-04       Impact factor: 4.124

4.  Bovine aortic endothelial cells display macrophage-like properties towards acetylated 125I-labelled low density lipoprotein.

Authors:  O Stein; Y Stein
Journal:  Biochim Biophys Acta       Date:  1980-12-05

5.  Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis.

Authors:  M T Quinn; S Parthasarathy; D Steinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

6.  Serum low density lipoproteins with mitogenic effect on cultured aortic smooth muscle cells.

Authors:  G M Fless; T Kirchhausen; K Fischer-Dzoga; R W Wissler; A M Scanu
Journal:  Atherosclerosis       Date:  1982-02       Impact factor: 5.162

7.  Human plasma platelet-activating factor acetylhydrolase. Purification and properties.

Authors:  D M Stafforini; S M Prescott; T M McIntyre
Journal:  J Biol Chem       Date:  1987-03-25       Impact factor: 5.157

8.  Autoxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes.

Authors:  H Esterbauer; G Jürgens; O Quehenberger; E Koller
Journal:  J Lipid Res       Date:  1987-05       Impact factor: 5.922

9.  Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit.

Authors:  T E Carew; D C Schwenke; D Steinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

10.  Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor.

Authors:  D M Stafforini; T M McIntyre; M E Carter; S M Prescott
Journal:  J Biol Chem       Date:  1987-03-25       Impact factor: 5.157

View more
  44 in total

1.  Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma.

Authors:  W Palinski; S Hörkkö; E Miller; U P Steinbrecher; H C Powell; L K Curtiss; J L Witztum
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

2.  Circulating platelet-activating factor is primarily cleared by transport, not intravascular hydrolysis by lipoprotein-associated phospholipase A2/ PAF acetylhydrolase.

Authors:  Jinbo Liu; Rui Chen; Gopal K Marathe; Maria Febbraio; Weilin Zou; Thomas M McIntyre
Journal:  Circ Res       Date:  2010-12-23       Impact factor: 17.367

3.  Oxidized LDL Levels Are Increased in HIV Infection and May Drive Monocyte Activation.

Authors:  David A Zidar; Steven Juchnowski; Brian Ferrari; Brian Clagett; Heather A Pilch-Cooper; Shawn Rose; Benigno Rodriguez; Grace A McComsey; Scott F Sieg; Nehal N Mehta; Michael M Lederman; Nicholas T Funderburg
Journal:  J Acquir Immune Defic Syndr       Date:  2015-06-01       Impact factor: 3.731

4.  Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein.

Authors:  S Hörkkö; E Miller; E Dudl; P Reaven; L K Curtiss; N J Zvaifler; R Terkeltaub; S S Pierangeli; D W Branch; W Palinski; J L Witztum
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

5.  Txnip ablation reduces vascular smooth muscle cell inflammation and ameliorates atherosclerosis in apolipoprotein E knockout mice.

Authors:  Chang Hyun Byon; Tieyan Han; Judy Wu; Simon T Hui
Journal:  Atherosclerosis       Date:  2015-06-03       Impact factor: 5.162

6.  Plasma levels of lipoprotein-associated phospholipase A(2) are increased in patients with β-thalassemia.

Authors:  Alexandros D Tselepis; George Hahalis; Constantinos C Tellis; Eleni C Papavasiliou; Panagiota T Mylona; Alexandra Kourakli; Dimitrios C Alexopoulos
Journal:  J Lipid Res       Date:  2010-07-12       Impact factor: 5.922

7.  Ultraviolet B radiation generated platelet-activating factor receptor agonist formation involves EGF-R-mediated reactive oxygen species.

Authors:  Yongxue Yao; Jay E Wolverton; Qiwei Zhang; Gopal K Marathe; Mohammed Al-Hassani; Raymond L Konger; Jeffrey B Travers
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

Review 8.  The biology of reactive intermediates in systemic lupus erythematosus.

Authors:  Jim C Oates
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

9.  UVB radiation-mediated inhibition of contact hypersensitivity reactions is dependent on the platelet-activating factor system.

Authors:  Qiwei Zhang; Yongxue Yao; Raymond L Konger; Anthony L Sinn; Shanbao Cai; Karen E Pollok; Jeffrey B Travers
Journal:  J Invest Dermatol       Date:  2008-01-17       Impact factor: 8.551

10.  The role of oxidized phospholipids in atherosclerosis.

Authors:  Judith A Berliner; Norbert Leitinger; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2008-12-04       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.